Nathan Davis
Analyst at RA Capital Management
Greater Boston
Overview
Work Experience
Board Observer
2021 - Current
Ansa Biotechnologies develops a novel DNA synthesis technology based on enzymes.
Raised $83,419,682.00 from Humboldt Fund, RA Capital Management, Fifty Years, Peak 6, Altitude Life Science Ventures, Fiscus Ventures, Northpond Ventures, Horizons Ventures, Mubadala Capital Ventures and Carbon Silicon Ventures.
Board Member
2021
Board Observer
2021
NanoMosaic provides solutions for early illness detection, prognostic monitoring, and biomarker identification.
Raised $40,750,000.00 from TigerGene, Insight Partners, TIME BioVentures, RA Capital Management and Pura Vida Investments.
Analyst
2022
Nate Davis is an Analyst on the Investment Team at RA Capital Management. Nate conducts due diligence on biotechnology companies at RA Capital and serves as a Board Director for The Covid Apollo Project and Nucleix. Previously, Nate worked closely with the Investment Team, as a Senior Associate within the TechAtlas division, to originate conviction in potential investments by identifying breakthroughs and putting data into context. Prior to RA Capital, Nate worked as an Investment Analyst at Wolfram Ventures. Nate has a BS in Biological Sciences from University of Vermont.
Associate
2019 - 2022
I am an Associate with the TechAtlas division of RA Capital Management. My primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities.
RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.
Executive Chair
2021 - 2023
Board Observer
2021 - 2022
3EO Health is to build a society in which everyone is empowered to optimize their health - for their patients, community, family.
Board Observer
2021 - 2022
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Raised $245,500,000.00 from RA Capital Management, Surveyor Capital, Perceptive Advisors, Acorn Bioventures, Paradigm BioCapital Advisors and Sands Capital Ventures.
Board Observer
2021 - 2021
MassConnect Mentor
2018 - 2019
Analyst
2017 - 2018
• Performed due diligence on investment candidates, including market dynamics, competitive landscape, and financial statements • Assisted potential candidates with go-to-market strategy, team creation and fundraising strategy